DEFITELIO
Total Payments
$33.0M
Transactions
4,871
Doctors
1,210
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $757,546 | 639 | 327 |
| 2023 | $1.2M | 822 | 297 |
| 2022 | $4.5M | 561 | 270 |
| 2021 | $2.4M | 825 | 316 |
| 2020 | $3.4M | 653 | 100 |
| 2019 | $20.7M | 1,371 | 264 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $30.3M | 1,207 | 91.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.3M | 394 | 4.0% |
| Consulting Fee | $647,995 | 138 | 2.0% |
| Grant | $317,126 | 3 | 1.0% |
| Travel and Lodging | $229,246 | 808 | 0.7% |
| Food and Beverage | $182,551 | 2,301 | 0.6% |
| Space rental or facility fees (teaching hospital only) | $37,050 | 15 | 0.1% |
| Education | $144.76 | 5 | 0.0% |
Payments by Type
Research
$30.3M
1,207 transactions
General
$2.7M
3,664 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 2, Prospective, Randomized, Open-label Study on the Efficacy of Defibrotide Added to Standard of Care Immunoprophylaxis for the Prevention of Acute Graft-versus-Host-Disease in Adult and Pediatric Patients After Allogeneic Hematopoietic Stem Cell Transplant | JAZZ PHARMACEUTICALS INC. | $9.5M | 0 |
| A PHASE 3, RANDOMIZED, ADAPTIVE STUDY COMPARING THE EFFICACY AND SAFETY OF DEFIBROTIDE VS BEST SUPPORTIVE CARE IN THE PREVENTION OF HEPATIC VENO-OCCLUSIVE DISEASE IN ADULT AND PEDIATRIC PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANT | JAZZ PHARMACEUTICALS INC. | $4.5M | 0 |
| A PILOT STUDY TO DETERMINE THE SAFETY OF DEFIBROTIDE IN CHILDREN WITH HIGH RISK KAWASAKI DISEASE | JAZZ PHARMACEUTICALS INC. | $3.3M | 0 |
| AN OPEN-LABEL STUDY OF DEFIBROTIDE FOR THE PREVENTION OF ACUTE GRAFT-VERSUS-HOST-DISEASE (AGVHD) | JAZZ PHARMACEUTICALS INC. | $2.8M | 0 |
| A SINGLE-ARM SAFETY AND FEASIBILITY STUDY OF DEFIBROTIDE FOR THE TREATMENT OF SEVERE COVID-19 | JAZZ PHARMACEUTICALS INC. | $2.0M | 0 |
| A PHASE II STUDY TO DETERMINE THE SAFETY OF DEFIBROTIDE IN SICKLE CELL DISEASE-RELATED ACUTE CHEST SYNDROME | JAZZ PHARMACEUTICALS INC. | $1.7M | 0 |
| DEFIBROTIDE TMA PROPHYLAXIS PILOT TRIAL | JAZZ PHARMACEUTICALS INC. | $1.6M | 0 |
| DEFIBROTIDE THERAPY FOR SARS-COV2 ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) | JAZZ PHARMACEUTICALS INC. | $474,454 | 0 |
| A PILOT TRIAL OF USING PRE-TRANSPLANT RISK STRATIFICATION AND PROPHYLACTIC DEFIBROTIDE TO PREVENT SERIOUS THROMBOTIC MICROANGIOPATHY IN HIGH-RISK HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS | JAZZ PHARMACEUTICALS INC. | $313,207 | 0 |
| PROSPECTIVE, MULTICENTER, OPEN-LABEL, SINGLE ARM, PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF DEFIBROTIDE IN THE PREVENTION OF CHIMERIC ANTIGEN RECEPTOR-T- CELL -ASSOCIATED NEUROTOXICITY IN SUBJECTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CEL | JAZZ PHARMACEUTICALS INC. | $297,333 | 0 |
| USING ULTRASOUND ELASTOGRAPHY TO PREDICT DEVELOPMENT OF HEPATIC SINUSOIDAL OBSTRUCTION SYNDROME | JAZZ PHARMACEUTICALS INC. | $289,585 | 0 |
| ULTRASOUND POINT SHEAR WAVE ELASTOGRAPHY (PSWE) FOR DIAGNOSIS OF HEPATIC VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) | JAZZ PHARMACEUTICALS INC. | $268,929 | 0 |
| PRE-CLINICAL INVESTIGATION OF TREATMENT OF RECENT-ONSET ISCHEMIC CENTRAL RETINAL VEIN OCCLUSION (ICRVO) WITH DEFIBROTIDE | JAZZ PHARMACEUTICALS INC. | $258,491 | 0 |
| NYMC-600 Phase II Intrapatient Open-Label Dose Escalation Trial of Defibrotide in Hematopoietic Cell Transplantation (HCT) Recipients with Sinusoidal Obstructive Syndrome (SOS) Post-HCT Associated with either Renal and/or Pulmonary Dysfunction with Either Refractory or Progressive Disease Following Defibrotide Therapy | JAZZ PHARMACEUTICALS INC. | $244,075 | 0 |
| THE SAFETY AND EFFICACY OF PROPHYLACTIC DEFIBROTIDE ADMINISTRATION IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH SICKLE CELL DISEASE FOLLOWING MYELOABLATIVE CONDITIONING (MAC) AND HAPLOIDENTICAL STEM CELL TRANSPLANTATION UTILIZING CD34 ENRICHMENT AND T-CELL (CD#) ADDBACK | JAZZ PHARMACEUTICALS INC. | $243,750 | 0 |
| USING ULTRASOUND ELASTOGRAPHY TO PREDICT DEVELOPMENT OF HEPATIC VENO-OCCLUSIVE DISEASE/SUNISOIDAL OBSTRUCTION SYNDROME. | JAZZ PHARMACEUTICALS INC. | $237,499 | 0 |
| JZP395-201: PROSPECTIVE, MULTICENTER, OPEN-LABEL, SINGLE ARM, PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF DEFIBROTIDE IN THE PREVENTION OF CHIMERIC ANTIGEN RECEPTOR T CELL ASSOCIATED NEUROTOXICITY IN SUBJECTS WITH RELAPSED OR REFRACTORY DIFFUSE L | JAZZ PHARMACEUTICALS INC. | $223,607 | 0 |
| DEFIBROTIDE THERAPY FOR SARS-COV2 ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) | Jazz Pharmaceuticals Inc. | $216,036 | 0 |
| DEFIBROTIDE IN ENDOTHELIAL CELL INJURY AND PLATELET ACTIVATION ASSOCIATED WITH SEVERE COVID-19 LINKED LONG HAULER SYNDROME AND NON COVID 19 ARDS, ACTIVITY AND EXPLORATION OF MECHANISIMS OF ACTION. | JAZZ PHARMACEUTICALS INC. | $176,730 | 0 |
| PA19-0756: PROSPECTIVE MULTI CENTER STUDY OF PEDIATRIC CELLULAR THERAPY PATIENTS AT RISK FOR ENDOTHELIAL DYSFUNCTION, SINUSOIDAL OBSTRUCTION SYNDROME AND/OR MULTI-ORGAN DYSFUNCTION SYNDROME (MODS) | JAZZ PHARMACEUTICALS INC. | $139,421 | 0 |
Top Doctors Receiving Payments for DEFITELIO — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD, MS | Pediatrics | Los Angeles, CA | $6,300 | 1 |
| , MBBS, MD, MRCP(U.K) | Pediatrics | Columbus, OH | $6,127 | 11 |
| , MD | Diagnostic Radiology | Minneapolis, MN | $6,125 | 9 |
| , MD | Pediatric Hematology-Oncology | Nashville, TN | $5,952 | 11 |
| , MD | Pediatric Radiology | Saint Louis, MO | $5,832 | 10 |
| , M.D | Hematology & Oncology | Baltimore, MD | $5,727 | 30 |
| Michelle Robbin | Diagnostic Radiology | Birmingham, AL | $5,580 | 8 |
| , MD | Hematology & Oncology | Chapel Hill, NC | $5,536 | 9 |
| , PA-C | Physician Assistant | Minneapolis, MN | $5,512 | 6 |
| , MD | Pediatric Radiology | Memphis, TN | $5,411 | 8 |
| , MD | Pediatric Hematology-Oncology | Atlanta, GA | $5,250 | 2 |
| , M.D | Surgery | Baltimore, MD | $4,860 | 2 |
| , M.D | Hematology & Oncology | Houston, TX | $4,815 | 5 |
| , MD | Internal Medicine | Chicago, IL | $4,607 | 7 |
| , DO | Hematology & Oncology | Richmond, VA | $4,328 | 2 |
| , MD | Internal Medicine | Milwaukee, WI | $4,313 | 6 |
| , MD | Medical Oncology | New York, NY | $4,240 | 1 |
| , M.D, M.P.H | Pediatrics | Minneapolis, MN | $4,200 | 1 |
| , MD | Hematology & Oncology | New York, NY | $3,857 | 7 |
| , MBBS MS | Internal Medicine | Ann Arbor, MI | $3,815 | 1 |
| , MD | Urology | Cleveland, OH | $3,780 | 1 |
| Randy Windreich | Pediatric Hematology-Oncology | Pittsburgh, PA | $3,764 | 2 |
| , M.D | Pediatric Hematology-Oncology | Boston, MA | $3,701 | 11 |
| , NP | Pediatrics | Memphis, TN | $3,610 | 10 |
| , MD | Pediatric Hematology-Oncology | Minneapolis, MN | $3,513 | 2 |
Ad
Manufacturing Companies
- JAZZ PHARMACEUTICALS INC. $32.4M
- Jazz Pharmaceuticals Inc. $632,633
Product Information
- Type Drug
- Total Payments $33.0M
- Total Doctors 1,210
- Transactions 4,871
About DEFITELIO
DEFITELIO is a drug associated with $33.0M in payments to 1,210 healthcare providers, recorded across 4,871 transactions in the CMS Open Payments database. The primary manufacturer is JAZZ PHARMACEUTICALS INC..
Payment data is available from 2019 to 2024. In 2024, $757,546 was paid across 639 transactions to 327 doctors.
The most common payment nature for DEFITELIO is "Unspecified" ($30.3M, 91.7% of total).
DEFITELIO is associated with 20 research studies, including "A Phase 2, Prospective, Randomized, Open-label Study on the Efficacy of Defibrotide Added to Standard of Care Immunoprophylaxis for the Prevention of Acute Graft-versus-Host-Disease in Adult and Pediatric Patients After Allogeneic Hematopoietic Stem Cell Transplant" ($9.5M).